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Heparin is a complex polysaccharide-based anticoagulant drug that is
essential for the practice of modern medicine [1]. Used in extracorporeal
therapies, such as kidney dialysis, in the treatment of coagulation disorders,
such as deep vein thrombosis (DVT), and to passivate the surfaces of
indwelling devices, such as catheters, a heparin-based product is the first
choice whenever blood clotting needs to be prevented or controlled.
There are three forms of heparin: unfractionated heparin (molecular weight
average MWavg  15 000), low molecular weight heparin (LMWH,
MWavg  6000), and ultra low molecular weight heparin (ULMWH,
MWavg < 2000) [1–3]. The most widely used form is unfractionated heparin,
a century-old drug prepared from animal tissues. Despite its widespread use
it has several limitations including required intravenous administration and
side effects such as heparin induced thrombocytopenia (HIT) and bleeding.
In the 1990s, LMWHs were introduced and they have successfully captured
a large share of the market becoming the anticoagulant of choice to treat
DVTs. LMWHs are prepared from animal-sourced unfractionated heparin
through controlled depolymerization. These have the major advantage of
being subcutaneously bioavailable and have a longer half-life allowing their
outpatient use and/or self-administration. A major disadvantage of LMWHs
is that, unlike unfractionated heparin, their anticoagulant effect is not
readily reversible, thus increasing the risk for bleeding due to overdosing.
The last decade has brought us ULMWHs (i.e., fondaparinux), first syn-
thesized by Sinay¨ et al. [4], which have well controlled pharmacokinetics/
pharmacodynamics, have no viral or prion impurities (possible in animal-
sourced materials), are subcutaneously bioavailable, and are manufactured
under current good manufacturing process (cGMP). Unfortunately, these
agents are very expensive and like LMWHs are not readily reversible.
In 2007–2008, there was a heparin crisis that resulted from contaminated
batches of heparin and LMWH entering the marketplace [5]. Severe side
effects (i.e., a rapid drop in blood pressure), some leading to death, were
ascribed to batches of contaminated unfractionated heparin imported from
China. This crisis led to the recall of much of the heparin on the market and
could have been a much greater problem had there not been sufficient
amounts of non-contaminated product to meet the needs of dialysis and
surgery patients. The contamination was traced to an adulteration of the crude
heparin precursor with an oversulfated chondroitin sulfate somewhere in the
process between the slaughterhouse where heparin was collected from pig
intestines and the pharmaceutical manufacturing site. While ULMWH was
not contaminated in the US, it could not be relied on to alleviate this crisis
because of its high cost, difficulty to produce in sufficient quantities to meet
worldwide needs, and limited utility for kidney dialysis. The inspection of
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graphs has reduced the likelihood of a similar crisis in the
future but the increased demand on heparin, as modern
medicine is applied to more of the world, and the limited
number of pigs (1 pig provides 3 doses of unfractionated
heparin or 1 dose of LMWH) pose constraints on the
supply of this critical drug. Since the crisis, the cost of
heparin active pharmaceutical ingredient (API) has
increased 10-fold.
Heparin is biosynthesized within the Golgi organelles of
mast cells that are most commonly found in intestine,
lung, liver and skin of higher animals [1]. Heparin bio-
synthesis, elucidated through the elegant work of Lin-
dahl et al. [6], starts with the building of its linear
polysaccharide backbone (even some bacteria are
capable of this step) through the synthase-catalyzed
alternating addition of two UDP-sugars. Backbone
sugars are enzymatically N-deacetylated, N-sulfonated,
O-sulfonated and epimerized at selected locations,
affording the highly sulfated heparin. The enzymes
involved in heparin biosynthesis are known and many
have been cloned in the past decade. These enzymes
have been largely used as tools by biochemists studying
heparin structure and biosynthesis [7]. While much is
now understood about their in vitro activity and speci-
ficity, little is known about how they are regulated and
controlled in vivo in the Golgi. It is clearly understood,
however, that the control of these enzymes could offer a
great potential in the preparation of synthetic unfractio-
nated heparin, LMWH and ULMWH. Moreover, it is
also possible to consider the preparation of designer
heparins [8] with reduced side effects (i.e., HIT), more
defined physical, chemical, biological, and pharmaco-
logical properties.
In 2007, our laboratories chemoenzymatically prepared a
small amount of bioengineered heparin from an Escher-
ichia coli-derived polysaccharide [9]. Others, including
Kuberan and Rosenberg [10], Lindahl and Casu [11],
and DeAngelis [12] had also used similar approaches to
prepare other heparin-like polysaccharides and oligosac-
charides. Over the past 4 years, we have been aggressively
examining the possibility of preparing sufficient
quantities of a bioengineered, unfractionated heparin
to meet the global supply needs (100 tons/yr.) as a
generic version of heparin [5,13]. The process begins
with an E. coli fermentation to prepare polysaccharide,
chemical de-N-acetylation, N-sulfonation a process that is
now moving to the kilogram scale. The use of recombi-
nant O-sulfotransferases and C5-epimerase results in a
bioengineered heparin that closely resembles the chemi-
cal and biological properties of heparin. One critical
component of this process is to reduce the cost of the
sulfotransferase cofactor and sulfo group-donor PAPS,
making up half the product mass, is being addressedCurrent Opinion in Pharmacology 2012, 12:217–219 by improved PAPS production and cofactor recycling
[14,15].
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Recently, our laboratories have announced a success in
preparing an ULMWH, similar to fondaparinux, using a
related chemoenzymatic process [3]. Instead of preparing
the oligosaccharide backbone through fermentation, it is
enzymatically synthesized by iterative addition of UDP-
sugars. This is again followed by the use of recombinant
O-sulfotransferases and C5-epimerase to afford a pure
ULMWH in over a 100-fold higher yield than possible
using chemical synthesis. The two ULMWH constructs
prepared showed comparable pharmacological properties
as fondaparinux. It remains to be seen whether this
chemoenzymatic process can be commercialized to afford
new ULMWHs for regulatory agency approval.In sum-
mary, heparin-based therapeutics are essential to modern
medicine and will remain an important class of drugs for
the foreseeable future. Modern biotechnological methods
are now available to bring more advanced manufacturing
process for heparins from the extractive methods devel-
oped in the early 20th century and the chemically syn-
thetic methods of the late 20th century into the new
millennium. The world is ready and waiting for the next
generation of synthetic heparin.www.sciencedirect.com
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